Studio sulla Sicurezza e sulla Farmacocinetica di BCD101 in Volontari Sani
Uno Studio Clinico di Fase 1, Randomizzato, in Doppio Cieco, a Singola/Multipla Somministrazione, con Escalation di Dose, per Valutare la Sicurezza, la Tollerabilità e le Caratteristiche Farmacocinetiche di BCD101 in Volontari Adulti Sani
A randomized, double-blinded, single/multiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.
The primary objectives of this study are to determine:
- The safety and tolerability of BCD101 in healthy adult volunteers.
- The pharmacokinetic profile of BCD101 following single and multiple dosing.
A control group is included, and dose cohorts will be compared to assess dose-dependent differences in safety, tolerability, and pharmacokinetics.
Key study activities include:
- Administration of single and multiple escalating doses of BCD101 and placebo under controlled conditions.
- Safety and tolerability assessments, including monitoring for adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs), and serious adverse drug reactions (SADRs).
- Pharmacokinetic (PK) analysis to evaluate the pharmacokinetic characteristics of the investigational product.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
North Chungcheong
-
Cheongju-si, North Chungcheong, Corea del Sud, 28644
- Chungbuk National University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
-
Inclusion Criteria
-
Healthy adult volunteers aged 19 years or older at screening.
-
Body weight ≥ 50.0 kg and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at screening.
* BMI (kg/m²) = weight (kg) / {height (m)}²
-
No congenital or chronic medical conditions requiring treatment, and no pathological signs or findings upon medical examination.
-
Clinical laboratory tests, vital signs, physical examination, and 12-lead electrocardiogram (ECG) results at screening indicate suitability for participation based on the characteristics of the investigational medicinal product.
-
Fully understood the detailed explanation of this clinical trial, voluntarily agreed to participate, and provided written informed consent agreeing to comply with study requirements during the trial period.
-
-
Exclusion Criteria
-
History or current clinically significant liver, kidney, neurological, psychiatric, respiratory, endocrine, hematological, neoplastic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal disorders.
-
Female subjects who are pregnant (urine hCG positive) or breastfeeding.
-
History of hypersensitivity (e.g., anaphylaxis, angioedema) or clinically significant allergic reactions to the active ingredient, excipients of the investigational product, or other medications (e.g., aspirin, penicillin antibiotics, macrolide antibiotics).
-
History of gastrointestinal diseases or surgeries that could affect absorption of the investigational drug (e.g., Crohn's disease, ulcers, acute or chronic pancreatitis), except simple appendectomy or hernia surgery.
-
Clinically significant abnormalities on 12-lead ECG at screening, including:
- QTc interval > 450 ms (males) or > 470 ms (females)
- PR interval > 200 ms
- QRS duration > 120 ms
-
Clinically significant laboratory abnormalities at screening, including:
- Liver function tests (AST, ALT, ALP, γ-GT, total bilirubin) exceeding twice the upper limit of normal.
- Serum creatinine outside the reference range or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m² as calculated by the CKD-EPI formula.
-
History of substance abuse or positive urine drug screening for abuse substances.
-
Vital signs at screening after at least 3 minutes of rest in a seated position meet any of the following:
-
Systolic blood pressure ≤ 90 mmHg or ≥ 150 mmHg
-
Diastolic blood pressure ≤ 60 mmHg or ≥ 100 mmHg
-
Pulse rate ≤ 40 bpm or ≥ 100 bpm
- Evidence of orthostatic hypotension at screening.
- Use of enzyme-inducing or inhibiting drugs such as barbiturates within 1 month prior to first dosing.
- Abnormal diet or consumption of foods that could affect drug absorption, distribution, metabolism, or excretion.
- Use of prescription or herbal medications that may affect the investigational product's characteristics within 2 weeks prior to first dosing, or over-the-counter drugs or dietary supplements within 10 days prior to first dosing (except when judged by the investigator not to affect the pharmacokinetics of the investigational product).
- Participation in another clinical trial with investigational drug administration within 6 months prior to first dosing (the end date of participation is calculated as the day after the last dose of the previous trial).
- Whole blood donation within 2 months prior to first dosing, platelet donation within 1 month prior to first dosing, blood transfusion within 1 month prior to first dosing, or inability to abstain from blood donation from informed consent to PSV.
- Excessive alcohol consumption (more than 21 units per week; 1 unit = 10 g = 12.5 mL pure alcohol) within 6 months prior to first dosing or inability to abstain from alcohol from informed consent to PSV.
- Smoking more than 10 cigarettes per day within 3 months prior to first dosing or inability to abstain from smoking from 24 hours prior to first dosing until last blood sampling.
- Consumption of grapefruit-containing foods within 72 hours prior to first dosing or inability to abstain until PSV.
- Consumption of caffeine-containing foods or beverages (e.g., coffee, green tea, black tea, carbonated drinks, coffee milk, energy drinks) from 24 hours prior to first dosing until last blood sampling or inability to abstain.
- Engaging in strenuous exercise exceeding daily activity levels from 48 hours prior to first dosing until PSV or inability to refrain from such exercise.
- Planning to become pregnant or not using reliable contraception methods (e.g., hormonal contraceptives, intrauterine device, sterilization procedures, barrier methods) for self or partner from informed consent until 90 days after last dose of investigational product.
- Any other reasons deemed by the investigator to make the subject unsuitable for participation.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: SAD-1(Treatment group)
6 Participants in the SAD-1(Treatment group) arm received a single oral dose of BCD101-1(2 sachets). BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial. |
[SAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at low concentration. [MAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at low concentration. |
|
Sperimentale: SAD-2(Treatment group)
6 Participants in the SAD-2(Treatment group) arm received a single oral dose of BCD101-2(2 sachets). BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial. |
[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration. [MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration. |
|
Sperimentale: SAD-3(Treatment group)
6 Participants in the SAD-3(Treatment group) arm received a single oral dose of BCD101-2(3 sachets). BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial. |
[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration. [MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration. |
|
Sperimentale: SAD-4(Treatment group)
6 Participants in the SAD-4(Treatment group) arm received a single oral dose of BCD101-2(4 sachets). BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial. |
[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration. [MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration. |
|
Sperimentale: MAD-1(Treatment group)
6 Participants in the MAD-1(Treatment group) arm received BCD101-1(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial. |
[SAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at low concentration. [MAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at low concentration. |
|
Sperimentale: MAD-2(Treatment group)
6 Participants in the MAD-2(Treatment group) arm received BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial. |
[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration. [MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration. |
|
Sperimentale: MAD-3(Treatment group)
6 Participants in the MAD-3(Treatment group) arm received a combination of BCD101-1(1 sachet) and BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet, while BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial. |
[MAD] A combination of BCD101-1(2 g) and BCD101-2(4 g) liquid formulations, administered orally as separate sachets simultaneously. Used for multiple dosing. |
|
Sperimentale: SAD-1(Placebo group)
2 Participants in the SAD-1(Placebo group) arm received a single oral dose of BCD101-P(2 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial. |
[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing. [MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing. |
|
Sperimentale: SAD-2(Placebo group)
2 Participants in the SAD-2(Placebo group) arm received a single oral dose of BCD101-P(2 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial. |
[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing. [MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing. |
|
Sperimentale: SAD-3(Placebo group)
2 Participants in the SAD-3(Placebo group) arm received a single oral dose of BCD101-P(3 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial. |
[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing. [MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing. |
|
Sperimentale: SAD-4(Placebo group)
2 Participants in the SAD-4(Placebo group) arm received a single oral dose of BCD101-P(4 sachets). BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial. |
[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing. [MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing. |
|
Sperimentale: MAD-1(Placebo group)
2 Participants in the MAD-1(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial. |
[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing. [MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing. |
|
Sperimentale: MAD-2(Placebo group)
2 Participants in the MAD-2(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days. BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient. The study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial. |
[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing. [MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing. |
|
Sperimentale: MAD-3(Placebo group)
2 Participants in the MAD-3(Placebo group) arm received BCD101-P(2 sachets), administered orally twice daily for 7 consecutive days. BCD101-P is a placebo liquid formulation identical in appearance and volume to the active formulations, containing no active ingredient. This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial. |
[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing. [MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With Adverse Events (Single-Ascending Dose, SAD)
Lasso di tempo: Day -1, Day 1, post-study visit (Day 4-7)
|
All adverse events occurring during the clinical trial following a single ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term. |
Day -1, Day 1, post-study visit (Day 4-7)
|
|
Physical Examination Abnormalities (SAD)
Lasso di tempo: Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported. |
Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
|
Vital signs: Systolic and Diastolic Blood Pressure (SAD)
Lasso di tempo: Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position. |
Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
|
Vital signs: Heart Rate (SAD)
Lasso di tempo: Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
Heart rate will be measured after at least three minutes of rest in the seated position. |
Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
|
Vital signs: Body Temperature (SAD)
Lasso di tempo: Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
Body temperature will be measured after at least three minutes of rest in the seated position. |
Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
|
Electrocardiogram (ECG) Abnormalities (SAD)
Lasso di tempo: Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported. |
Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
|
Laboratory Abnormalities (SAD)
Lasso di tempo: Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported. |
Screening, Day -1, Day 1, post-study visit (Day 4-7)
|
|
Number of Participants With Adverse Events (MAD)
Lasso di tempo: Day -1 through Day 7, and post-study visit (Day 8-12)
|
All adverse events occurring during the clinical trial following a multiple ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term. |
Day -1 through Day 7, and post-study visit (Day 8-12)
|
|
Physical Examination Abnormalities (MAD)
Lasso di tempo: Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
|
A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported. |
Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
|
|
Vital signs: Systolic and Diastolic Blood Pressure (MAD)
Lasso di tempo: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
|
Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position. |
Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
|
|
Vital signs: Heart Rate (MAD)
Lasso di tempo: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
|
Heart rate will be measured after at least three minutes of rest in the seated position. |
Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
|
|
Vital signs: Body Temperature (MAD)
Lasso di tempo: Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
|
Body temperature will be measured after at least three minutes of rest in the seated position. |
Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
|
|
Electrocardiogram (ECG) Abnormalities (MAD)
Lasso di tempo: Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
|
A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported. |
Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
|
|
Laboratory Abnormalities (MAD)
Lasso di tempo: Screening, Day -1, Day 1, Day 6-7, post-study visit (Day 8-12)
|
Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported. |
Screening, Day -1, Day 1, Day 6-7, post-study visit (Day 8-12)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax) (SAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose)
|
Cmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101. |
Day 1 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) (SAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose)
|
AUC0-t will be calculated using non-compartmental analysis following a single ascending dose of BCD101. |
Day 1 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) (SAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose)
|
AUCinf will be calculated using non-compartmental analysis from the plasma concentration-time profile following a single ascending dose of BCD101. |
Day 1 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) (SAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose)
|
Tmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101. |
Day 1 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameter: Terminal Elimination Half-Life (t1/2) (SAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose)
|
Terminal elimination half-life will be estimated from the terminal phase of the plasma concentration-time profile following a single ascending dose of BCD101. |
Day 1 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameter: Maximum Plasma Concentration at Steady State (Cmax,ss) (MAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
Cmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101. |
Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameters: Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau,ss) (MAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
AUCtau,ss will be calculated at steady state during multiple ascending dosing (Day 1-7). |
Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity at Steady State (AUCinf,ss) (MAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
AUCinf,ss will be calculated using non-compartmental analysis from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101. |
Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration at Steady State (Tmax,ss) (MAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
Tmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101. |
Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameter: Terminal Elimination Half-Life at Steady State (t1/2,ss) (MAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
Terminal elimination half-life at steady state will be estimated from the terminal phase of the plasma concentration-time profile following multiple ascending doses of BCD101. |
Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
|
|
Pharmacokinetic Parameter: Accumulation Ratio (Rac) (MAD)
Lasso di tempo: Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)
|
Rac will be calculated to assess the accumulation of BCD101 following multiple ascending doses. |
Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- BCD101
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .